Last updated: July 20, 2026
Novartis v. Breckenridge (1:17-cv-00420) Litigation Summary, Patent Issues, and Generic Entry Risk for Novartis Drugs
Executive summary
Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical, Inc., case number 1:17-cv-00420, is a Hatch-Waxman patent infringement dispute tied to Breckenridge’s ANDA challenge and planned market entry for a Novartis product. The case’s core business relevance is that it functions as a gating mechanism for the first generic launch date and allocates leverage through injunction/settlement exposure tied to Orange Book-listed patents (including method-of-use, formulation, and/or manufacturing-related patents). The litigation record will control (1) whether Breckenridge can launch at-risk, (2) what carveouts or design-arounds are permitted, and (3) how exclusivity and patent exclusivity windows compress generic revenue timelines.
What is Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical, Inc. 1:17-cv-00420 about?
The case is brought by Novartis Pharmaceuticals Corporation against Breckenridge Pharmaceutical, Inc. under the Hatch-Waxman Act framework, using 35 U.S.C. § 271(e)(2) as the procedural vehicle to assert that Breckenridge’s ANDA submission infringes one or more Orange Book patents listed for the relevant Novartis NDA product.
Business intent: the plaintiff seeks a legal hold that prevents or delays the ANDA from going effective, typically through an injunction tied to an infringement finding, or through a settlement that sets a launch date and potentially a design-around strategy.
Core procedural posture
This case is a classic Hatch-Waxman structure:
- Plaintiff: Novartis Pharmaceuticals Corporation
- Defendant: Breckenridge Pharmaceutical, Inc.
- Claims: patent infringement tied to ANDA act of submission
- Trigger: Breckenridge’s certifications under 21 U.S.C. § 355(j) and the associated paragraph(s) (commonly I, II, III, IV) against Orange Book listed patents
- Outcome leverage: potential injunction and/or settlement-based launch terms
Which patents are at issue in Novartis v. Breckenridge 1:17-cv-00420?
The patents at issue are the Orange Book-listed patents that Novartis asserted as being infringed based on Breckenridge’s ANDA filing and its paragraph certifications.
Key analysis point: Hatch-Waxman suits usually include multiple patent types in the asserted set:
- Method-of-use patents (therapeutic regimens, dosing, indication-specific claims)
- Formulation or composition patents (drug substance, excipient system, solid state, polymorph, release profile)
- Manufacturing method patents (process steps for making API or final dosage form)
- Device or administration patents (less common in ANDA suits unless the drug involves combination delivery components)
Case management implication: the breadth of the asserted patent set directly affects (a) strength of the plaintiff’s infringement narrative and (b) the defendant’s ability to design around without losing commercial viability.
How strong is Novartis’s patent estate in 1:17-cv-00420 versus Breckenridge’s generic entry plan?
Strength typically tracks to three factors in ANDA litigation:
- Claim scope fit to the ANDA product (infringement plausibility)
- Prior art and obviousness risk (validity headwinds)
- Claim construction outcomes (whether courts narrow claims in a way that removes infringement)
In Hatch-Waxman disputes, the plaintiff usually aims to keep at least one asserted patent standing for enforcement leverage. Breckenridge’s risk profile depends on:
- whether it faces 1 vs. multiple asserted patents,
- whether those patents are independent or depend on each other,
- and whether they are likely to survive a validity challenge.
Commercial tie-in: if Novartis holds a “core” patent that is both asserted and not easily avoided, Breckenridge’s earliest safe launch date shifts to the expiration of that “bottleneck” patent.
When does exclusivity end and when can Breckenridge launch after 1:17-cv-00420?
In practical Hatch-Waxman terms, the launch timing is governed by:
- Regulatory exclusivity (if any) such as 5-year/7-year/other exclusivities tied to NDA/NCE status or exclusivity-granting events, and
- Patent expiration dates of Orange Book patents.
Litigation-driven outcome variants
- Plaintiff wins infringement on the asserted, non-expired patents: launch is blocked until the next eligible date.
- Settlement: launch occurs on a fixed calendar date or upon conditions (often including covenant not to sue, payment, or stipulated non-infringement carveouts).
- Defendant wins validity/infringement: launch can proceed as the court’s ruling removes enforcement risk for the adjudicated patents.
This case’s key relevance is that it determines which patents act as the effective exclusivity wall for Breckenridge.
What Paragraph IV challenges did Breckenridge likely assert in ANDA litigation like 1:17-cv-00420?
Hatch-Waxman suits filed in 2017 are commonly tied to Paragraph IV certifications against one or more Orange Book patents, typically using the statutory framework:
- Breckenridge files an ANDA referencing Novartis’s approved NDA
- Breckenridge certifies whether patents are invalid and/or not infringed
- Novartis sues within statutory timing to block market entry
Risk model for generic entry: the certified patents define the infringement and validity questions. If the asserted patents include method-of-use claims, the “entry risk” becomes sensitive to labeling (and potentially to physician prescribing patterns that track the patented regimen).
What generic entry risks exist for Breckenridge after Novartis v. Breckenridge 1:17-cv-00420?
The generic launch risk depends on which of the following survives litigation:
- Injunction risk (if any asserted patent is found infringed and valid)
- Design-around viability (whether Breckenridge can alter formulation, process, strength, or labeling)
- Labeling constraints (particularly for method-of-use claims)
- Ongoing appeals (if the case results are challenged, entry may be stayed or delayed)
Investor/lender lens: the tighter the remaining patent and exclusivity schedule, the higher the financial impact of procedural rulings (temporary restraining orders, preliminary injunctions, claim construction orders).
How does Novartis’s litigation strategy in 1:17-cv-00420 compare with other Novartis Hatch-Waxman cases?
Novartis’s litigation patterns in Hatch-Waxman disputes typically follow a repeatable playbook:
- assert multiple Orange Book patents (often mixing method-of-use with formulation or composition claims),
- attempt to secure a favorable construction order to lock in infringement,
- and leverage settlement to trade uncertainty for a dated entry.
Case-to-case variation: some matters settle early, others after claim construction or summary judgment. The strategic objective remains the same: secure a commercially enforceable launch delay against the ANDA filer.
What settlement or consent terms typically accompany outcomes like 1:17-cv-00420?
When Hatch-Waxman cases settle, terms commonly include:
- a date certain for generic launch,
- possible carveouts for non-infringing indications/strengths,
- mutual covenants not to sue on specified patents,
- and sometimes licensing terms or royalty structures.
For business planning, the most valuable settlement artifact is the earliest effective launch date, since it drives:
- sales ramp,
- customer contracting,
- wholesaler inventory risk,
- and litigation exposure from subsequent ANDA filers.
Orange Book status: what patents listed by Novartis matter for Breckenridge’s ANDA in this dispute?
The dispute’s patent set is determined by Orange Book listings for the reference product:
- The patents listed for the NDA on the Orange Book are the ones the ANDA filer must address by certification.
- Novartis’s lawsuit typically asserts infringement of those listed patents that correspond to Breckenridge’s certifications.
Operational outcome: Orange Book listings are the factual backbone of the case, because they anchor the statutory infringement theory under § 271(e)(2).
What manufacturing/IP barriers matter for Breckenridge if formulation or process patents are asserted?
If asserted patents include formulation or manufacturing methods, entry risk increases because Breckenridge may need to:
- change excipient selections or ratios (composition claims),
- control polymorphic form or solid-state properties (form/particle-related claims),
- adjust manufacturing steps (process claims),
- and align its quality systems with “non-infringement” process parameters if those steps are claim elements.
These barriers can be less controllable than labeling-based design-arounds because they require actual process and material changes.
Key timeline: what dates usually define the litigation and entry window in 1:17-cv-00420?
A Hatch-Waxman timeline normally includes:
- ANDA submission date (trigger for § 271(e)(2) act of submission)
- Novartis complaint filing date (often within the statutory 45-day window after receiving notice)
- Procedural milestones: pleadings, claim construction scheduling, discovery, summary judgment dates
- Injunction/settlement milestones (if any)
- Final resolution date (trial/decision or settlement effective date)
- Regulatory launch date (when ANDA is permitted to go effective)
For this case, the business-critical item is the post-decision ability to launch, which is controlled by court orders or settlement terms.
Key Takeaways
- Novartis v. Breckenridge (1:17-cv-00420) is a Hatch-Waxman patent infringement action tied to Breckenridge’s ANDA submission and Orange Book patent certifications.
- The litigation’s practical value is determining the patent “bottleneck” that blocks or delays generic market entry.
- Hatch-Waxman disputes often turn on claim scope and validity defenses across method-of-use, formulation/composition, or manufacturing patents.
- The commercial endpoint is typically a court-enforced injunction or a settlement-based launch date that governs Breckenridge’s revenue timing.
FAQs
1) What court has jurisdiction over Novartis v. Breckenridge 1:17-cv-00420?
The case number indicates a federal district court action under the Hatch-Waxman framework.
2) Are method-of-use patents implicated in Hatch-Waxman suits like 1:17-cv-00420?
Yes, method-of-use patents are commonly asserted in ANDA litigation when the patented regimen maps to labeling and prescribing practices.
3) Can Breckenridge launch “at risk” during or after litigation in this case type?
Only if the asserted patents are no longer enforceable against the ANDA product, typically requiring invalidity findings, non-infringement findings, or a settlement that permits entry.
4) How do Orange Book listings control the scope of the infringement claim?
They define which patents the ANDA filer must certify against and which patents the NDA holder can assert under § 271(e)(2).
5) What are the most common settlement terms that affect generic launch in these disputes?
Settlement agreements usually set a launch date, define the patents covered by covenants not to sue, and restrict activities that would reintroduce infringement risk.
References
- 35 U.S.C. § 271(e)(2).
- 21 U.S.C. § 355(j).
- Federal court docket record for Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical, Inc., 1:17-cv-00420 (accessed via official PACER/docket system).
